Esperion Therapeutics (NASDAQ:ESPR) Given Market Outperform Rating at JMP Securities

Esperion Therapeutics (NASDAQ:ESPR)‘s stock had its “market outperform” rating reaffirmed by analysts at JMP Securities in a report issued on Tuesday,Benzinga reports. They presently have a $4.00 price target on the biopharmaceutical company’s stock, down from their previous price target of $7.00. JMP Securities’ price objective indicates a potential upside of 112.77% from the stock’s current price.

ESPR has been the topic of several other reports. HC Wainwright reissued a “buy” rating and set a $16.00 target price on shares of Esperion Therapeutics in a research note on Tuesday. Cantor Fitzgerald assumed coverage on Esperion Therapeutics in a research report on Tuesday, December 17th. They set an “overweight” rating and a $8.00 price target on the stock. Needham & Company LLC restated a “buy” rating and set a $6.00 price objective on shares of Esperion Therapeutics in a research report on Friday, December 13th. The Goldman Sachs Group assumed coverage on Esperion Therapeutics in a report on Wednesday, December 18th. They issued a “neutral” rating and a $4.00 target price on the stock. Finally, StockNews.com cut shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, November 15th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, Esperion Therapeutics has an average rating of “Hold” and a consensus target price of $6.75.

Esperion Therapeutics Price Performance

Esperion Therapeutics stock opened at $1.88 on Tuesday. Esperion Therapeutics has a fifty-two week low of $1.58 and a fifty-two week high of $3.94. The firm’s 50 day simple moving average is $2.28 and its 200-day simple moving average is $2.12. The company has a market cap of $370.44 million, a P/E ratio of -2.94 and a beta of 1.01.

Institutional Trading of Esperion Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the business. The Manufacturers Life Insurance Company acquired a new position in shares of Esperion Therapeutics during the 2nd quarter worth $159,000. SG Americas Securities LLC boosted its holdings in Esperion Therapeutics by 105.9% in the third quarter. SG Americas Securities LLC now owns 77,049 shares of the biopharmaceutical company’s stock worth $127,000 after purchasing an additional 39,635 shares in the last quarter. Boomfish Wealth Group LLC increased its position in Esperion Therapeutics by 17.1% during the third quarter. Boomfish Wealth Group LLC now owns 34,997 shares of the biopharmaceutical company’s stock worth $58,000 after buying an additional 5,102 shares during the last quarter. Traphagen Investment Advisors LLC bought a new position in Esperion Therapeutics during the third quarter valued at about $27,000. Finally, Versor Investments LP acquired a new stake in shares of Esperion Therapeutics in the third quarter worth about $44,000. 47.39% of the stock is currently owned by institutional investors and hedge funds.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.